- Home
- CADL vs XOMAP Comparison
CADL vs XOMAP Comparison
Compare CADL & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | XOMAP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | N/A |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | XOMAP |
|---|---|---|
| Price | $5.51 | $26.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.43 | N/A |
| AVG Volume (30 Days) | ★ 982.0K | N/A |
| Earning Date | 11-13-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | N/A |
| 52 Week High | $13.68 | N/A |
Technical Indicators
Market Signals| Indicator | CADL | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 57.58 |
| Support Level | $5.39 | $26.50 |
| Resistance Level | $6.83 | $26.85 |
| Average True Range (ATR) | 0.43 | 0.17 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 45.81 | 85.33 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.